Summary

The neuropathic pain market was valued at $7,717.4 million in 2022 and is estimated to reach $13,248.3 million by 2032, exhibiting a CAGR of 5.6% from 2023 to 2032. Neuropathic pain is caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain manifest in various ways, including stabbing, burning, tingling, or shooting sensations. It is often chronic and is challenging to treat. Various conditions that lead to neuropathic pain are diabetic neuropathy, postherpetic neuralgia (resulting from shingles), and trigeminal neuralgia.
Major factors that drive the growth of the global neuropathic pain market include advancements in drug of neuropathic pain; rise in number of research regarding neuropathic pain medication; and increase in number of patients suffering from neuropathic pain. Furthermore, surge in demand for medication of neuropathic pain, increase in awareness regarding diabetic neuropathy, upsurge in target population, and rise in number of clinical trials for the development of neuropathic pain boost the growth of neuropathic pain market. For instance, in October 2023, AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system announced that the company's presentation at the pain conference held by the Swedish Pain Society is now available in its entirety on the company's website. The presentation contains clinical data from the phase II study with the company's leading drug candidate in pain, ACD440, which is being developed for the treatment of peripheral neuropathic pain.

However, the side effects of neuropathic pain medicines and high cost of branded medications are expected to restrict the growth of neuropathic pain market. On the contrary, surge in healthcare expenditure and unmet medical demands to get better treatment options in developing countries are expected to create lucrative opportunities for the expansion of the global market in the future.
The neuropathic pain market is segmented on the basis of drug class, indication, distribution channel, and region. On the basis of drug class, the market is divided into antidepressants, anticonvulsant, opioids, capsaicin, and others. The antidepressants segment is further categorized into tricyclic antidepressants and serotonin–noradrenaline reuptake inhibitors (SNRI). On the basis of indication, the market is classified into diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others. On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The major players profiled in the report are Abbott Laboratories, Collegium Pharmaceutical, Inc., Eli Lilly and Company, Glenmark Pharmaceuticals Limited, Grünenthal, Mallinckrodt Pharmaceuticals, Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. These major players have adopted agreement, acquisition, clinical trial, and product approval as key developmental strategies to improve the product portfolio of the neuropathic pain market.

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neuropathic pain market analysis from 2022 to 2032 to identify the prevailing neuropathic pain market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the neuropathic pain market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global neuropathic pain market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Go To Market Strategy
● Market share analysis of players by products/segments
● New Product Development/ Product Matrix of Key Players
● Additional company profiles with specific to client's interest
● Additional country or region analysis- market size and forecast
● Average Selling Price Analysis / Price Point Analysis
● Brands Share Analysis
● Expanded list for Company Profiles
● Historic market data
● SWOT Analysis
Key Market Segments
By Drug class
● Antidepressants
○ Type
○ Tricyclic Antidepressants
○ Serotonin–Noradrenaline Reuptake Inhibitors (SNRI)
● Anticonvulsant
● Opioids
● Capsaicin
● Others
By Indication
● Diabetic Neuropathy
● Spinal Stenosis
● Chemotherapy-Induced Peripheral Neuropathy
● Others
By Distribution channel
● Hospital Pharmacies
● Drugs Stores and Retail Pharmacies
● Online Pharmacies
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ Australia
○ India
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Pfizer Inc.
○ Teva Pharmaceuticals
○ Novartis AG
○ Eli Lilly and Company.
○ Mallinckrodt Pharmaceuticals
○ Collegium Pharmaceutical Inc
○ Sun Pharmaceutical Industries Ltd.
○ Abbott Laboratories
○ Glenmark Pharmaceuticals Limited
○ Grunenthal GmbH.

ページTOPに戻る

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in cases of neuropathic pain
3.4.1.2. Rise in prevalence of chronic diseases
3.4.1.3. Rise in geriatric population
3.4.2. Restraints
3.4.2.1. Side effects of neuropathic pain medicine
3.4.3. Opportunities
3.4.3.1. Rise in number of drugs in pipeline
CHAPTER 4: NEUROPATHIC PAIN MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Antidepressants
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Antidepressants Neuropathic Pain Market by Type
4.3. Anticonvulsant
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Opioids
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Capsaicin
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: NEUROPATHIC PAIN MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Diabetic Neuropathy
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Spinal Stenosis
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Chemotherapy-Induced Peripheral Neuropathy
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Others
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
CHAPTER 6: NEUROPATHIC PAIN MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Drugs Stores and Retail Pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: NEUROPATHIC PAIN MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Drug class
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by Distribution channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Drug class
7.2.5.1.2. Market size and forecast, by Indication
7.2.5.1.3. Market size and forecast, by Distribution channel
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Drug class
7.2.5.2.2. Market size and forecast, by Indication
7.2.5.2.3. Market size and forecast, by Distribution channel
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Drug class
7.2.5.3.2. Market size and forecast, by Indication
7.2.5.3.3. Market size and forecast, by Distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Drug class
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by Distribution channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Drug class
7.3.5.1.2. Market size and forecast, by Indication
7.3.5.1.3. Market size and forecast, by Distribution channel
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Drug class
7.3.5.2.2. Market size and forecast, by Indication
7.3.5.2.3. Market size and forecast, by Distribution channel
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Drug class
7.3.5.3.2. Market size and forecast, by Indication
7.3.5.3.3. Market size and forecast, by Distribution channel
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Drug class
7.3.5.4.2. Market size and forecast, by Indication
7.3.5.4.3. Market size and forecast, by Distribution channel
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Drug class
7.3.5.5.2. Market size and forecast, by Indication
7.3.5.5.3. Market size and forecast, by Distribution channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Drug class
7.3.5.6.2. Market size and forecast, by Indication
7.3.5.6.3. Market size and forecast, by Distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Drug class
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by Distribution channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Drug class
7.4.5.1.2. Market size and forecast, by Indication
7.4.5.1.3. Market size and forecast, by Distribution channel
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Drug class
7.4.5.2.2. Market size and forecast, by Indication
7.4.5.2.3. Market size and forecast, by Distribution channel
7.4.5.3. Australia
7.4.5.3.1. Market size and forecast, by Drug class
7.4.5.3.2. Market size and forecast, by Indication
7.4.5.3.3. Market size and forecast, by Distribution channel
7.4.5.4. India
7.4.5.4.1. Market size and forecast, by Drug class
7.4.5.4.2. Market size and forecast, by Indication
7.4.5.4.3. Market size and forecast, by Distribution channel
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Drug class
7.4.5.5.2. Market size and forecast, by Indication
7.4.5.5.3. Market size and forecast, by Distribution channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Drug class
7.4.5.6.2. Market size and forecast, by Indication
7.4.5.6.3. Market size and forecast, by Distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Drug class
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by Distribution channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Drug class
7.5.5.1.2. Market size and forecast, by Indication
7.5.5.1.3. Market size and forecast, by Distribution channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Drug class
7.5.5.2.2. Market size and forecast, by Indication
7.5.5.2.3. Market size and forecast, by Distribution channel
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Drug class
7.5.5.3.2. Market size and forecast, by Indication
7.5.5.3.3. Market size and forecast, by Distribution channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Drug class
7.5.5.4.2. Market size and forecast, by Indication
7.5.5.4.3. Market size and forecast, by Distribution channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Pfizer Inc.
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Teva Pharmaceuticals
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Glenmark Pharmaceuticals Limited
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Novartis AG
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Mallinckrodt Pharmaceuticals
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Eli Lilly and Company.
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Grunenthal GmbH.
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Collegium Pharmaceutical Inc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Sun Pharmaceutical Industries Ltd.
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Abbott Laboratories
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance